4th Inflammasome Therapeutics Summit

The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma, biotechs, and academic KOLs, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs, which are shaking up the immunology R and D landscape.

As the space eagerly awaits data readouts from proof-of-concept trials, and with more companies than ever before with active inflammasome therapeutic
pipelines; this is your opportunity to be involved in interactive discussions on:

- Deciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system
- Overcoming limitations of preclinical models, identifying clinically meaningful biomarkers of inflammasome inhibition, and defining good clinical endpoints
- Taming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets
- Delving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful

Join 120+ fellow peers and industry heavyweights this Fall including NodThera, Novartis, Zyversa Therapeutics, and more, to build meaningful partnership and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality.

Speakers: Alan Watt, Chief Scientific Officer, NodThera, Bruno Reversade, Professor and Director, Laboratory of Human Genetics and Therapeutics GIS and IMCB, A*STAR, Niccolo Pengo, Chief Scientific Officer, Mabylon, Pablo Pelegrin, Scientific Deputy Director and Principal Investigator, BioMedical Research Institute of Murcia (IMIB-Arrixaca), University of Murcia, Ashley Mansell, Head of Translational Sciences, Adiso Therapeutics, Hao Wu, Asa and Patricia Springer Professor, Boston Children's Hospital and Harvard Medical School, Karen Cashmere, Chief Commercial Officer, ZyVersa, Tamara Seredenina, Senior Scientist, AC Immune, Bryan Oronsky, Chief Development Officer, EpicentRx, Juan Pablo de Rivero Vaccari, Associate Professor of Neurological Surgery and The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Liang Shan, Assistant Professor, Washington University School of Medicine, Marc Pelletier, Senior Principal Scientist - Translational Immune Oncology, Novartis, Adam Keeney, President and Chief Executive Officer, NodThera, Kate Fitzgerald, Professor and Vice Chair, Department of Medicine Division of Innate Immunity, University of Massachusetts Chan Medical School, Michael Crackower, Chief Scientific Officer, Ventus Therapeutics, Richard Gordon, Group Leader - Clinical Neuroscience, University of Queensland, Daniel Bachovchin, Assistant Member, Memorial Sloan Kettering Cancer Center, Eva Mracsko, Senior Scientist, Roche, Kevin Wilhelmsen, Associate Director of Immunology, BIOAGE Labs, Stephen Glover, Co-Founder, Chairman and Chief Executive Officer, ZyVersa, Anil Goyal, Chief Executive Officer and Board Director, IMMvention Therapeutix, David Bearss, Chief Executive Officer and President, Halia Therapeutics, Giulia D'Urso, Senior Scientist - Clinical, Roche, Jonathan Kagan, Professor - Pediatrics, The President and Fellows of Harvard College, Kate Schroder, Affiliate Professor, University of Queensland, Robert Keane, Professor, University of Miami, Salvatore Alesci, Chief Scientific Officer, Invea Therapeutics, Vishal Singh, Assistant Professor - Nutritional Sciences and Microbiome, Penn State, Dianne McKay, Professor of Immunology and Microbiology, The Scripps Research Institute, Hal Hoffman, Professor of Pediatrics and Medicine and Chief of the Division of Allergy, Immunology and Rheumatology in the Department of Pediatrics, UC San Diego/Rady Children's Hospital, Marianthi Papakosta, Associate Director NeuroInflammation/ Neurodegeneration, Takeda

Others Details

Brochure: https://go.evvnt.com/1252816-3?pid=6581